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Abstract
Background and study aims : The most important causes of 
hereditary colorectal cancer are Lynch syndrome (LS) and the 
adenomatous polyposis syndromes (familial adenomatous poly-
posis syndrome or FAP, attenuated FAP or AFAP and MUTYH 
associated polyposis syndrome or MAP). The aim of this study 
was to investigate whether all patients with a hereditary syndrome 
within one center receive uniform advice regarding surveillance 
and treatment.
Patients and methods : A retrospective analysis was performed 
of all electronic patient health records of patients with LS, FAP, 
AFAP and MAP who received genetic counselling or were followed 
by a health care specialist at the University Hospital in Ghent.  
Results : Data from 122 patients were collected. For all patients, 
recommendations from the medical genetics department were 
highly consistent. Adherence to their recommendations was good 
within the center for the management of colon polyps. There was 
a lack of consistency in the screening and surveillance advice for 
other tumors in departments other than gastroenterology. Only 33 
patients had systematic follow-up consultations to check results 
and organize surveillance.
Conclusion : Previously, small studies have suggested that 
patients with hereditary gastrointestinal cancer syndromes 
infrequently have surveillance as specified in the guidelines. This 
study shows almost uniform recommendations and good adherence 
for surveillance of the colon, but incomplete or contradictory 
advice for surveillance of other organs.  The need for an integrated 
approach from a multidisciplinary team will only increase in the 
future, because more families with hereditary cancer are likely to 
be found due to the increased use of next generation sequencing 
in cancer diagnostics. (Acta gastroenterol. belg., 2020, 83, 399-405).
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Introduction
Colorectal cancer (CRC) is a frequent and poten-
tially lethal disease. Most tumors are sporadic, but 
approximately 20 to 30% of patients with CRC have 
a family history of the disease. In 5 to 6% a germline 
mutation, diagnostic for a known hereditary cancer 
syndrome, can be identified (1,2). The most common 
syndromes are Lynch Syndrome (LS) (also called 
hereditary non-polyposis colorectal cancer or HNPCC) 
and the familial adenomatous polyposis syndromes. 
LS is an autosomal dominant inherited disorder caused 
by a mutation in one of the mismatch repair (MMR: 
MLH1, MSH2, MSH6, PMS2) genes, leading to tumor 
DNA microsatellite instability (MSI). Patients with 
LS have an estimated lifetime cumulative incidence of 
80% for CRC and 60% for endometrial cancer (EC). In 
addition, there is also an increased risk for other tumors 
such as stomach, small intestine, pancreas, bile duct, 
ovary, urinary tract and brain cancer. Unfortunately, this 
syndrome is often under-diagnosed, leading to significant 
morbidity and mortality (3). 
The familial adenomatous polyposis syndromes consist 
of three hereditary syndromes in which the inheritance 
of a germline mutation causes accelerated colorectal 
carcinogenesis, which is manifested by the development 
of multiple adenomas at a young age with the potential 
for early development of CRC. We distinguish familial 
adenomatous polyposis syndrome (FAP), attenuated 
familial adenomatous polyposis syndrome (AFAP) and 
MUTYH-associated polyposis syndrome (MAP). FAP 
and AFAP have an autosomal dominant inheritance 
pattern. These disorders are often caused by a mutation in 
the APC gene (4). FAP is defined by the presence of more 
than 100 synchronous colorectal adenomas, whereas in 
AFAP there are typically fewer than 100 adenomas. 
It is characterized by a later onset of the disease and 
adenomas are often located more proximally. In addition 
to the increased risk for CRC, there is also an increased 
incidence of duodenal and ampullary tumors, thyroid 
cancer, hepatoblastoma and desmoid tumors. 
MAP is caused by a biallelic mutation of the MUTYH 
gene and is inherited autosomal-recessively. The con-
dition is characterized by the presence of multiple 
adenomatous polyps, often 20 to 99, similar to AFAP 
(4,5).
Patients with a hereditary gastrointestinal cancer 
syndrome are recommended to undergo surveillance in 
order to detect premalignant lesions and small tumors, 
thereby decreasing morbidity and mortality of associated 
cancers. Small studies have already suggested that many 
individuals do not have surveillance as specified in the 
guidelines and it has also been described that patients 
often receive different advice from their various health 
care providers (6,7). It is unclear whether inadequate 
surveillance is the result of patient non-compliance or 
rather incorrect recommendations from physicians. 
The purpose of this monocentric study was to investi-
gate whether all patients with a hereditary syndrome 
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found. For surveillance of the colon, a colonoscopy was 
recommended starting from the age of 20-25 years, every 
1-2 years. In 2 out of 10 (20%) patients with an MSH6 
mutation, it was specifically mentioned that surveillance 
could be postponed until the age of 30, as CRC occurs 
later in life than in other MMR gene mutations. In 20 of 
73 patients (27%) it was stated that a total colectomy is 
preferable compared to a partial colectomy in the case of 
development of a CRC.
Screening for gynecological tumors was advised by 
means of a gynecological examination with transvaginal 
ultrasound and determination of CA 125, starting from 
the age of 30-35 years, to be repeated every 1-2 years. 
In only 11 of the 37 female patients (30%), an annual 
endometrial sampling was recommended. A prophylactic 
hysterectomy with bilateral salpingo-oophorectomy at 
the completion of child-bearing was recommended to 
6 patients with an MLH1 mutation and 1 patient with a 
MSH6 mutation (7/37, 19%) with the specific advice that 
the risk of gynecological tumors is strongly increased in 
women with these mutations. No advice was given to the 
remaining 30 patients, but 7 (23%) of them had already 
undergone a prophylactic hysterectomy.
Surveillance for gastric tumors was recommended by 
means of an esophagogastroduodenoscopy (EGD) every 
1-2 years, starting from the age of 30-35 years.
For the surveillance of urinary tract tumors, it was 
recommended to perform an abdominal ultrasound 
and a urinalysis, starting from the age of 30-35 years, 
every 1-2 years. To 1 patient, only annual urinalysis was 
recommended.
Two patients with a family history of brain tumors 
received advice to screen by means of a neurological 
examination and, optionally, an MRI of the brain. Finally, 
an annual dermatological check-up was recommended 
to 2 patients. One patient received the advice to seek 
optimal sun protection. 
Advice in other departments
Data on follow-up was retrieved for 35 patients: 20 
patients were seen exclusively in Ghent and 15 patients 
were also partially followed in an external center. For 
27 patients at least one contact at the gastroenterology 
department was recorded. Five patients were seen at the 
surgical department and 21 patients had a contact in one 
of the following departments : gynecology, neurology, 
receive uniform advice regarding surveillance and 
treatment, or whether there are differences in the recom-
mendations given by the various sub-disciplines where 
they are followed up. 
Patients and Methods
This was a retrospective, single-center study regarding 
patients with a confirmed diagnosis of LS, (A)FAP or 
MAP, carried out at a tertiary hospital (Ghent University 
Hospital). 
Data were collected from the database of the medical 
genetics department. A list of all patients who had under-
gone genetic screening for LS, (A)FAP or MAP during the 
period from 01/01/2007 up to 31/12/2016 was obtained. 
Four hundred and seventy patients with a confirmed 
genetic mutation (out of 4631 screening episodes) were 
identified. A review of the electronic patient files was 
performed and only patients that had received genetic 
counselling or were followed by a health care specialist 
within the university center were included in the study. 
79 patients with LS, 35 patients with FAP, 7 with 
AFAP and 1 with MAP were included in the study. Some 
patients were index patients, others had been screened 
because of a known familial hereditary cancer syndrome. 
An overview of the departments where patients received 
follow-up and the recommendations for individual 
patients given regarding surveillance, prevention and 
treatment of tumors, was made. The number of patients 
who were lost-to-follow-up was also recorded. A sum-
mary of the number of patients, the reason for their diag-
nosis and the involved disciplines is shown in table 1. 
This study was approved by the Ethics Committee of 
Ghent University hospital.  
Results
Lynch syndrome
A total of 79 patients (40 female; 39 male) who 
received genetic counseling and/or sought specialist 
advice regarding surveillance following the diagnosis of 
LS were identified. 
Advice in the department of medical genetics
In 73 out of 79 patients (37 female, 25 male), written 




Reason for diagnosis Follow-up at 
the surgery 
department








LS 79 22 index patients, 21 with cancer, 3 metastatic
49 with known family history
8 without information
5 27 21 73
FAP 35 3 index patients, 1 with metastatic cancer
16 with known family history
14 13 12 27
AFAP/
MAP
8 2 index patients, both with cancer, 1 metastatic
6 without information
2 1 0 8
Table 1. — Overview of the patients followed in Ghent University Hospital
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Twenty-one patients were also regularly seen by 
health care professionals of other disciplines. The 
majority of these patients only received advice about sur- 
veillance within the practitioners discipline and the 
recommendations were variable (see table 3). 
Follow-up
Out of 35 patients with at least some record of follow-
up, 30 patients were followed at the gastroenterology 
and / or surgery department. Of these 30 patients, only 
15 (50%) had an annual or 2- yearly appointment in the 
hospital, where all results and necessary examinations 
were discussed and planned.  Four patients were only 
seen at the endoscopy department during their follow-up, 
two of whom also had surveillance of the other organ 
systems. In total, 6 patients (20%) were lost to follow-up. 
FAP, AFAP and MAP
A total of 43 patients with adenomatous polyposis 
syndromes were identified:  35 patients with FAP, 7 with 
AFAP and 1 with MAP. 
Advice in the department of medical genetics
Thirty-five patients received genetic counseling 
regarding surveillance and treatment (27 patients with 
FAP, all with AFAP and MAP).
In patients with an APC mutation, an annual colono-
scopy was recommended, starting from the age of 10-
12 years. Only 1 (3.7%) of the 27 FAP patients was 
advised to start with a flexible sigmoidoscopy and only 
to proceed to a total colonoscopy if polyps were detected. 
In 5 patients with AFAP a total colonoscopy was 
recommended starting from the age of 10-12 years, the 
other 2 were recommended to start at 18-20 years. To the 
patient with MAP, a total colonoscopy was recommended 
starting from the age of 25-30 years, every 2-3 years. 
Twenty-six of the 27 (96%) FAP patients were advised 
to undergo a prophylactic colectomy with ileoanal pouch 
urology, dermatology, oncology, endocrinology or radio-
therapy.
The advice given at the gastroenterology department 
is shown in table 2. Written advice on surveillance was 
found in 21 out of 27 patients (78%). Of the remaining 6 
patients, 3 were only seen at the endoscopy department, 
with no further advice being prescribed. Two patients 
were only seen after surgery for a CRC, setting the 
indication for chemotherapy, after which they returned to 
an external center. One patient died before formal advice 
could be given. 
Five patients with a history of CRC were followed up 
at the surgical department after resection of their primary 
tumor. In 3 patients, no advice for further surveillance 
was written down, but 1 of them had a metastatic tumor. 
The 2 remaining patients were advised to perform an 
annual colonoscopy. Gynecological examination and an 
EGD was recommended to the one female patient. No 
advice was given regarding surveillance of urinary tract 
tumors. 
Exam Number Frequency and age of 
onset
Colonoscopy 21/21 (100%) Every 1-2 years (n=10)
Every year (n=10)
Every 2 years (n=1)









Every 1-2 years (n=7)
Every year (n=1)
Age of onset: 30-35 years
EGD 21/21 (100%) Every 1-2 years (n=10)
Every year (n=10)
Every 2 years (n=1)









Every 1-2 years (n=11)
Every year (n=8)








Table 2. — Recommendations from the gastroenterology 
department regarding surveillance of patients with LS
Discipline Number Recommendations
Neurology 2 - Annual neurological examination and MRI of the brain (n=1)
- 2-yearly MRI of the brain (n=1)
Dermatology 2 - Annual examination is possible but not necessary (n=1)
- 6-monthly follow-up given the history of skin tumors (n=1)
Endocrinology 2 - No systematic surveillance for thyroid cancer (n=1)
- Annual surveillance after thyroidectomy (n=1)
Urology 4 - Annual urinalysis, cystoscopy/ CT scan if necessary (n=1)
- No routine surveillance recommended, only if hematuria (n=1)
- 6- monthly follow-up given the history of urological tumors (n=1)
- No advice (follow-up prostate cancer) (n=1)
Gynecology 6 - No written advice (n=1)
- Annual follow-up with gynecological examination (n=3), vaginal ultrasound (n=2), CA 125 (n=4) and 
   endometrial sampling (n=2) starting at 35-40 year
- Hysterectomy (n=3), bilateral salpingo-oophorectomy after completion of childbearing
- 6- monthly gynecological examination, annual colonoscopy and ultrasound of the kidneys (n=1)
Radiotherapy 4 - No written advice
Medical Oncology 1 - EGD every 3 years, annual colonoscopy, urine analysis and ultrasound (n=1)
Table 3. — Recommendations from various departments regarding surveillance of patients with LS
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Two out of 14 patients who had at least one contact 
at the gastroenterology department (13 with FAP, 1 with 
MAP) were only referred for a second opinion regarding 
the treatment of duodenal polyps, after which they were 
referred back to an external center. Sixteen patients (14 
with FAP, 2 with AFAP and 1 with MAP) were seen at the 
surgery department. Two patients had a metastatic tumor 
and surveillance measures were deemed inappropriate. 
No written advice was recorded in 7 out of 14 remaining 
patients (50%). Six of these patients were postoperatively 
referred to another department or an external center. One 
patient was only seen pre-operatively. 
Follow-up
Out of the 25 patients with at least one contact at 
the gastroenterology, surgery or pediatrics department, 
18 patients had a regular (annual to 2-yearly) follow- 
up consultation. A total of 8 patients (32%) were lost-
to-follow-up: 4 children at the pediatrics department, 
1 patient who did not receive follow-up after surgery 
(neither at the department of surgery, nor at the pediatrics 
department), 2 patients who were followed at the 
gastroenterology and surgery department and 1 patient 
from the gastroenterology department. Of these, only 
one patient was picked up for further surveillance after 
a number of years.
Discussion
Present guidelines regarding the surveillance and 
treatment of patients with LS, (A)FAP and MAP vary to 
some extent between countries and organisations (tables 
6 and 7). The differences in recommendations regarding 
screening, surveillance and surgery for polyps and colon 
(IPAA) or ileorectal anastomosis (IRA), to be carried out 
‘at relatively young age’. 
Surveillance of the stomach and duodenum was 
recommended to all patients by means of an EGD at the 
age of 20-25 years, to be repeated every 1-3 years.
Screening for thyroid cancer by performing an annual 
clinical examination and an ultrasound was recommended 
in FAP and AFAP patients, starting from the age of 10-12 
years. This advice was uniform except for one patient, in 
whom a 3-monthly clinical examination with evaluation 
of TSH and free thyroxine value was recommended 
starting from birth.
A final recommendation concerns the screening for 
hepatoblastoma. Overall, a clinical examination with 
liver palpation, ultrasound and determination of the AFP 
value was advised annually, starting from birth up to the 
age of 7 years. To one patient it was recommended that 
surveillance could be stopped at the age of 5 years. To 
another patient a more intensive screening was proposed 
with a three-monthly determination of the AFP value and 
an ultrasound; for a third patient it was stated that there 
was no consensus about the screening frequency, ranging 
from 1 time every 3 months to annually. 
Advice in other departments
Eighteen out of 43 patients had surveillance in an 
external center. The remaining 25 had at least one 
follow-up contact : 18 were seen exclusively at the Ghent 
university hospital and 7 partly in an external center. 
Sixteen patients had at least one contact at the surgical 
department, 14 at the gastroenterology department, 
10 at the department of pediatrics and 2 patients were 
followed at other departments. The advice given at the 
gastroenterology, surgery and pediatrics department is 
shown in table 4 and 5. 




Number Frequency Number Frequency
Colonoscopy 11 (79%) Yearly 7 (100%) 1-2 yearly (6), no interval reported (1)
EGD 12 (86%) Yearly (3), 2- yearly (1), according to 
Spigelman stage (6); not reported (2)
5 (71%) Yearly (3), 2- yearly (1), no interval reported (1)
Thyroid examination 
and ultrasound 5 (36%) Yearly (5) 1 (14%) 2- yearly
Table 4. — Recommendations from the gastroenterology and surgery department for patients with FAP/AFAP/MAP
Exam Number Frequency and age of onset
Clinical examination 5 (50%) Every year (n= 4) or every 3 months (n= 1)
Starting from birth
Liver palpation, ultrasound and AFP 6 (60%) Every 3 months (n=1 ), every year (n= 4) or every 6 months (n= 1)
Starting from birth up to the age of 7 years (n= 5) or 5 years (n = 1)
Colonoscopy 9 (90%) Every year (n= 9)
Age of onset: 10-12 years
EGD 5 (50%) Every 1 – 3 year (n= 4)
Age of onset: 20-25 years (n= 4) or 15 years (n= 1)
Palpation and ultrasound of the thyroid gland 5 (50%) Every year (n = 4) or every 3 months (n= 1)
Age of onset: 10-12 years (n= 4) or 16–18 years (n = 1)
Abdominal ultrasound for detection of desmoid tumors 1 (10%) Every year
Table 5. — Recommendations from the pediatrics department for patients with FAP
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coordinated follow-up. Overall, advice on screening and 
surveillance for colon polyps as well as surgery were in 
accordance with international guidelines – both for LS 
and polyposis syndromes. However, surveillance for 
other tumors, most importantly endometrial and ovarian 
cancer, but also urinary tract in LS and thyroid cancer in 
polyposis, is less well organized. It is possible that we 
underestimated the number of patients that undergo the 
proper examinations in other hospitals, but for those that 
have surveillance in our center, advices vary considerably 
between departments. Again, this is not due to a change 
in institutional guidelines over time. The variability in 
advice may be explained by the fact that evidence in the 
medical literature on the benefit of surveillance for these 
tumors is less specific and recommendations in different 
guidelines also vary. Consequently, the advice from the 
different departments are not in themselves ‘wrong’, 
but ideally they should be uniform and in accordance 
with the recommendations given at the medical genetics 
department, which can easily be found in the electronic 
patient files.
cancer are small, but advice regarding risk-management 
for associated tumors is variable and mainly based on 
expert opinion given the lack of high-quality studies.
Previously, small studies have already suggested 
that many individuals with a hereditary gastrointestinal 
cancer syndrome do not have surveillance as specified in 
the guidelines and it has also been described that patients 
often receive different advice from their various health 
care providers (6,7). In this study, little variation was 
seen in the initial proposal for surveillance, as written 
down by the department of genetics in the 73 patients 
with LS and 35 patients with polyposis syndromes. 
Whatever small variation was noted, was not due to 
changes in institutional guidelines over time, but more 
to an accent given by the physician at the time of the 
consultation. Despite clear written recommendations 
from the medical genetics department, follow-up was 
not uniformly organized and sometimes different 
advice was given in the various departments were 
patients received their follow-up. The fact that some 
patients combine exams in different hospitals also 

















AFAP/MAP Colonoscopy 18-20 2
1 when adenoma







AFAP Colonoscopy 18-20 1-2
1 when adenoma
ACG (7) FAP Sigmoidoscopy/colonoscopy Puberty 1 Colectomy AFP  and 
ultrasound
0 till 7 2
AFAP/MAP Colonoscopy 1







AFAP/MAP Colonoscopy 18-20 2
1 when adenoma





AFAP Colonoscopy 20 2
MAP Colonoscopy 20 1








ESMO FAP/AFAP EGD with duodenoscope
Consider videocapsule
25-30 According to Spigelman stage US 25-30 1
MAP /
ASCO FAP/AFAP EGD with duodenoscope 25-30 According to Spigelman stage Consider US 25-30 1
MAP /
ACG FAP/AFAP EGD with duodenoscope
Random biopsies fundic gland 
polyps
25-30 According to Spigelman stage US 1
MAP
Marllorca FAP/AFAP EGD with duodenoscope 25-30 According to Spigelman /
MAP
ASCRS FAP/AFAP EGD with duodenoscope 20-25 According to Spigelman
stage
Consider US 1
MAP EGD with duodenoscope 30 /
Table 6. — Recommendations in literature for surveillance in FAP/AFAP/MAP patients
Abbreviations : IRA : ileorectal anastomosis ; IPAA : Ileo-anal pouch anastomosis ; EGD : esophagogastroduodenoscopy ; US : ultrasound.
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pathway has multiple causes. First, there is often a lack 
of responsibility assumed for surveillance follow-up, 
allowing individuals to be overlooked by the different 
caring systems (19). The content of information that 
patients receive, a good communication and knowledge 
about the disease are important factors that contribute 
to compliance and especially a good guidance from 
health care professionals appears to be very important 
(20-22). It has already been hypothesized that the 
presence of a designated team leader for these patients is 
associated with more thorough and organized screening 
systems and leads to a better compliance (18). Second, 
specialists themselves confirm that they often have a 
lack of knowledge regarding oncogenetics and express 
educational needs regarding this. Indeed patients often 
describe important differences in the support they receive 
from their doctors and up to one third experienced 
difficulties in finding health care providers who were 
Most importantly, only a low number of patients (15 
patients with LS and 18 with FAP/AFAP/MAP) were 
seen at consultation to discuss the results of the exams 
and to organize the next surveillance. These patients did 
not organize all surveillance examinations in our hospital, 
but are the only ones for whom we can be sure that all 
exams were performed regularly. In addition, 20% of 
patients with LS and 32% of patients with FAP were lost 
to follow-up, which is a fairly high percentage. Whether 
this is due to insufficient compliance of the patient or 
caused by incomplete or incorrect recommendations 
from the health care professionals is unclear.
The problem of variable recommendations and non-
compliance has already been described in literature and 
there is some evidence that healthcare systems might 
actually create barriers to screening through ineffective 
coordination of care, lack of continuity and disparate 
recommendations (18). This failure in the patient care 
Table 7. — Recommendations in literature for surveillance in Lynch patients
Colon Ovaries/endometrium
What Start (y) Frequency (y) Alternative What Start (y) Frequency (y)
ACG (7) Colonoscopy 20-25 1-2 Colectomy if CRC TVUS+ES 30-35 1
Hysterectomy and BSO 40-45
MST (1) 20-25
2-5y before youngest family
member if < 25
1-2 (partial) colectomy TVUS+ES 30-35 1
if not controlable Hysterectomy 40
Mallorca (8) 20-25 1-2 (partial) colectomy TVUS+ES 35-40 1-2
if CRC Hysterectomy and BSO 40
NCCN (3) 20-25
2-5y before youngest family







<5y before youngest family
member if < 25
1-2 (partial) colectomy
if CRC, to discuss
with patient
TVUS+ES+CA125 30-35 1
Hysterectomy and BSO 35
ASCO (2) 20-25
<5y before youngest family
member if < 25







AGA (9, 10) 20-25
<5y before youngest family




What Start (y) Frequency (y) What Start (y) Frequency (y)
ACG EGD + biopsy Screening for HP 30-35 3-5 if family history No surveillance recommended
MST EGD + biopsy 30-35 2-3 if risk factors Urinalysis 30-35 1
Screening for HP
Mallorca EGD in countries with high ncidence 25 1-2 Urine cytology + US if MSH2 30-35 1
One- off screening for HP
NCCN EGD + biopsy if high incidence 30-35 3-5 Urinalysis 30-35 1
Consider screening for HP
ESMO EGD if high incidence 1-3 No surveillance recommended
Screening for HP
ASCO EGD of high incidence 1-3 No surveillance recommended
Screening for HP
AGA / /
Abbreviations : TV US : transvaginal ultrasound ; ES : endometrial sampling ; BSO: bilateral ; EGD : esophagogastroduodenoscopy ; HP : Helicobacter Pylori ; 
US : ultrasound.
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knowledgeable about Lynch syndrome (6). Additional 
training for doctors and better awareness of hereditary 
cancer syndromes seems appropriate. Lastly, there often 
seems to be a lack of information exchange between 
health care professionals (23). Given that patients with 
LS and FAP have an increased risk of multiple tumors, 
a multidisciplinary approach seems legitimate. The 
importance of good integrated care has already been 
confirmed in the literature, where it was shown that 
compliance was significantly higher in specific colorectal 
cancer clinics than in other centers (19). 
This study has some limitations. First, the cohort was 
relatively small. Second, it was a retrospective analysis, 
based on the information that was found in the electronic 
patient record, so verbally delivered information could 
not be included. 
In conclusion, a number of recommendations can be 
made with regard to the follow-up and surveillance of 
patients with hereditary cancer syndromes. There is a 
need for in integrated approach from a multidisciplinary 
team and uniform recommendations. The patient should 
be well informed regarding surveillance and a health care 
practitioner should take responsibility to coordinate all 
investigations. An annual, preferably multidisciplinary, 
outpatient check-up with discussion of all results and 
the planning of future investigations should be offered 
to reduce the risk of missing important investigations as 
much as possible. 
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